Alexandra Bryson

Alexandra Bryson

Auto-generated profile, based on publicly available information

Alexandra Bryson

Virginia Commonwealth University Medical Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Transplantation Proceedings
Verified
Journal Article
Closed access
JCJohanna Christensen
Johanna Christensen
DKDhiren Kumar
Dhiren Kumar
IMIrfan Moinuddin
Irfan Moinuddin
ABAlexandra Bryson
Alexandra Bryson
ZKZahra Kashi
Zahra Kashi
GGGaurav Gupta
Gaurav Gupta

10 April 2024 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
ABAlexandra L. Bryson
Alexandra L. Bryson
ABAmira Bhalodi
Amira Bhalodi
RLRachael M. Liesman
Rachael M. Liesman
AMAmy J. Mathers
Amy J. Mathers
Traditionally, cephalothin susceptibility results were used to predict the susceptibility of additional cephalosporins; however, in 2013–2014, the Clinical and Laboratory Standards Institute (CLSI) revisited this practice and determined that cefazolin is a more accurate proxy than cephalothin for uncomplicated urinary tract infections (uUTIs). Therefore, a cefazolin surrogacy breakpoint was established to predict the susceptibility of seven oral cephalosporins for Escherichia coli , Klebsiella pneumoniae , and Proteus mirabilis in the context of uUTIs. Clinical microbiology laboratories face several operational challenges when implementing the cefazolin surrogacy breakpoint, which may lead to confusion for the best path forward. Here, we review the historical context and data behind the surrogacy breakpoints, review PK/PD profiles for oral cephalosporins, discuss challenges in deploying the breakpoint, and highlight the limited clinical outcome data in this space.

6 August 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
MBMorgan L. Bixby
Morgan L. Bixby
EDEllora C. Daley
Ellora C. Daley
LCLindsey B. Collins
Lindsey B. Collins
JSJenna M. Salay
Jenna M. Salay
ABAlexandra L. Bryson
Alexandra L. Bryson
EHElizabeth B. Hirsch
Elizabeth B. Hirsch
Despite the first-line recommendation of fosfomycin for uncomplicated urinary tract infections (UTIs), there are pressing barriers for optimizing its use for the treatment of non- Escherichia coli Enterobacterales UTI. There are no approved breakpoints for oral use against other Enterobacterales, and the recommended agar dilution (AD) reference method for minimal inhibitory concentration (MIC) determination is largely impractical. Using 160 clinical Klebsiella pneumoniae isolates, we sought to understand rates of skipped wells and MIC imprecision in broth microdilution (BMD) and how that compares to rates of error using AD. Though the Clinical and Laboratory Standards Institute refers to the skipped well phenomena in their recommendation against the use of BMD, there is a paucity of data on its frequency. While AD and BMD produced similar MIC 50/90 values (32/256 µg/mL for AD and 64/256 µg/mL for BMD), essential agreement was poor. No-growth wells at concentrations below the MIC occurred in up to 10.9% of wells at a given concentration, as the most frequent scientific error. Growth in concentrations above the measured MIC occurred in up to 3.3% of wells and was seen within three dilutions of the MIC for BMD. Observation of single colonies either at or beyond the measured MIC for AD was also common and occurred up to 8.3% and 2.5% of the time, respectively. The frequent scientific error in both testing methods should prompt re-evaluation of AD guidelines and expansion of MIC testing methods for fosfomycin susceptibility testing, as poor agreement with another method prone to scientific error should not be the main detractor from BMD use. IMPORTANCE: Despite the recommendation of fosfomycin for uncomplicated urinary tract infections (UTIs), there are barriers for optimizing its use. There are no approved breakpoints for oral use against other Enterobacterales, and the recommended agar dilution (AD) reference method for MIC determination is largely impractical. The use of broth microdilution (BMD) for fosfomycin testing is not recommended by the Clinical and Laboratory Standards Institute due to unsatisfactory precision and skipped wells—occurrence of no-growth in a single well before the minimal inhibitory concentration (MIC)—and trailing endpoints. We sought to understand rates of skipped wells and growth at concentrations above measured MICs in BMD and how that compares to scientific error using AD. No-growth wells at concentrations below the MIC occurred in up to 10.9% of wells for BMD and single colonies at or beyond measured MICs for AD were also common. Frequent scientific error in both methods should prompt re-evaluation of both AD and BMD for fosfomycin susceptibility testing.

18 August 2021 in Transplantology
Verified
Journal Article
Open access
PDF file
RWRyan Winstead
Ryan Winstead
JCJohanna Christensen
Johanna Christensen
SSSara Sterling
Sara Sterling
MMMegan Morales
Megan Morales
DKDhiren Kumar
Dhiren Kumar
GGGaurav Gupta
Gaurav Gupta
Information regarding Coronavirus disease 2019 in the transplant population is lacking. Recently it has been suggested that cycle threshold values obtained on polymerase chain reaction tests may serve as a marker of disease severity with lower values (i.e., higher viral load) being associated with higher mortality. This study was done to assess the impact of remdesivir use on the time to a negative COVID-19 PCR as well as the degree of change between two Ct’s based on treatment. A total of 30 kidney transplant patients with a new diagnosis of COVID-19 were assessed. Serial PCR results were followed from the time of diagnosis then every 2–4 weeks until negative. In patients who received remdesivir immediately after COVID-19 confirmation compared to no remdesivir, time to negative PCR was not statistically different with a median duration of 57 days in both groups (p = 0.369). The change in the Ct between the first and the second PCR test was also not statistically different between groups with a median change of 18.4 cycles in the remdesivir group and 15.7 cycles without remdesivir (p = 0.516). The results of this small single-center analysis suggest that remdesivir may not be beneficial in shortening time to a negative COVID-19 PCR.

2 March 2022 in Transplant Infectious Disease
Verified
Journal Article
Open access
PDF file
NVNicole C. Vissichelli
Nicole C. Vissichelli
MMMegan Morales
Megan Morales
ABAlexandra Bryson
Alexandra Bryson
DBDavid Bruno
David Bruno
Click on the article title to read more.

3 October 2025 in Transplantation Direct
Verified
Journal Article
Open access
MMMarisa Mihori
Marisa Mihori
ABAlexandra Bryson
Alexandra Bryson
CDChristopher Doern
Christopher Doern
FFFreba Farhat
Freba Farhat
GLGuanhua Lai
Guanhua Lai
NVNicole C. Vissichelli
Nicole C. Vissichelli